Action Resmed - 0KW4

Votre Hub pour des idées et discussions en direct en temps réel

Premium

Dernier

102,85

Prix Achat

0,00

Prix Vente

0,00

Volume échangé

188

0,00 Fourchette du Jour 0,00

102,85 Plage de 52 semaines 102,85

Cap du marché

15,109B

Clôture Veille

102,85

Ouverture

Dernière Transaction

231.94

(O)

Dernière heure de transaction

Volume financier

VWAP

Volume moyen (3 m)

576

Actions en circulation

146 907 000

Rendement du Dividende

Ratio Cours sur Bénéfices

33,60

Bénéfice par action (BPA)

6,95

Chiffre d'affairess

4,69B

Bénéfice net

1,02B

Secteur

Surgical,med Instr,apparatus

Industrie

Surgical,med Instr,apparatus

Site Web

www.resmed.com

Siège social

Wilmington, Delaware, USA

Fondé

Resmed Inc est coté dans le secteur Surgical,med Instr,apparatus de la London Stock Exchange avec le ticker 0KW4. Le dernier cours de clôture d'Resmed était de US$102,85. Au cours de la dernière année, les actions de Resmed ont été négociées dans une fourchette de prix de US$ 102,85 à US$ 102,85.

Resmed compte actuellement 146 907 000 actions en circulation. La capitalisation boursière d'Resmed est de US$15,11 milliard. Resmed a un ratio cours/bénéfice (ratio PE) de 33.60.

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep New insights from 30,026 people across 13 markets show the...

Vaping Expected to Increase COPD Health and Economic Burden by 2050

Vaping Expected to Increase COPD Health and Economic Burden by 2050 New ResMed-supported research presented at ERS 2024 projects future Chronic...

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia ResMed studies...

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis 36,000 people across 17 markets responded to the company’s fourth annual...

ResMed Adopts New Operating Model to Accelerate Long-term Growth

ResMed Adopts New Operating Model to Accelerate Long-term Growth Justin Leong appointed Chief Product Officer, effective immediately.Katrin...

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software Expands ResMed’s sleep management software...

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP The studies...

Période	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	102.85	102.85	102.85	58	102.85	DE
4	102.85	102.85	102.85	396	102.85	DE
12	102.85	102.85	102.85	576	102.85	DE
26	102.85	102.85	102.85	885	102.85	DE
52	102.85	102.85	102.85	1271	102.85	DE
156	102.85	102.85	102.85	1599	102.85	DE
260	102.85	102.85	102.85	1120	102.85	DE

0KW4 - Frequently Asked Questions (FAQ)

What is the current Resmed share price?

The current share price of Resmed is US$ 102,85

How many Resmed shares are in issue?

Resmed has 146 907 000 shares in issue

What is the market cap of Resmed?

The market capitalisation of Resmed is USD 15,11B

What is the 1 year trading range for Resmed share price?

Resmed has traded in the range of US$ 102,85 to US$ 102,85 during the past year

What is the PE ratio of Resmed?

The price to earnings ratio of Resmed is 33,6

What is the cash to sales ratio of Resmed?

The cash to sales ratio of Resmed is 7,32

What is the reporting currency for Resmed?

Resmed reports financial results in USD

What is the latest annual turnover for Resmed?

The latest annual turnover of Resmed is USD 4,69B

What is the latest annual profit for Resmed?

The latest annual profit of Resmed is USD 1,02B

What is the registered address of Resmed?

The registered address for Resmed is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Resmed website address?

The website address for Resmed is www.resmed.com

Which industry sector does Resmed operate in?

Resmed operates in the SURGICAL,MED INSTR,APPARATUS sector

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
AMGOAmigo Holdings Plc	0,475p (72,73%)	11,81M
BEMBeowulf Mining Plc	22,00p (25,71%)	104,2k
WSGWestminster Group Plc	1,30p (23,81%)	1,4M
BLOEBlock Energy Plc	1,00p (21,21%)	11,06M
SMLStrategic Minerals Plc	0,30p (20,00%)	11,23M
SSTScottish Oriental Smaller Companies Trust Plc	290,00p (-95,96%)	76,08k
ONCOncimmune Holdings Plc	1,40p (-43,78%)	1,57M
BMTOBraime Group Plc	1 350,00p (-20,59%)	547
PYXPyx Resources Limited	1,97p (-19,76%)	398,74k
MGAMMorgan Advanced Materials Plc	214,50p (-16,21%)	8,59M
TRPTower Resources Plc	0,0245p (6,52%)	775,51M
UKOGUk Oil & Gas Plc	0,01125p (-4,26%)	434,61M
TW.Taylor Wimpey Plc	114,25p (2,05%)	345,64M
LLOYLloyds Banking Group Plc	72,32p (0,84%)	344,78M
PREMPremier African Minerals Limited	0,0205p (-11,26%)	300,49M

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resmed Inc (0KW4)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Resmed Inc

0KW4 Dernières nouvelles

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Vaping Expected to Increase COPD Health and Economic Burden by 2050

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed Adopts New Operating Model to Accelerate Long-term Growth

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP

3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023

ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer

ResMed Chief Administrative Officer and Global General Counsel to Retire

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Vaping Expected to Increase COPD Health and Economic Burden by 2050

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

0KW4 - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Resmed Inc (0KW4) Cours

Resmed Inc (0KW4)

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

À propos de Resmed Inc

0KW4 Dernières nouvelles

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Vaping Expected to Increase COPD Health and Economic Burden by 2050

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

ResMed Adopts New Operating Model to Accelerate Long-term Growth

ResMed Acquires Somnoware, a Leader in Digital Sleep and Respiratory Care Diagnostics Software

PAP Adherence Lowers ER Visits 24-36% in 1 Year for People with Sleep Apnea and Heart Failure: ResMed Studies Presented at SLEEP

3 World-Renowned Sleep Apnea Experts Present New Benefits of PAP Therapies at ATS 2023

ResMed Appoints Michael Rider its Next Global General Counsel, Dawn Haake its First Chief Quality Officer

ResMed Chief Administrative Officer and Global General Counsel to Retire

ResMed’s Fifth Annual Global Sleep Survey Reveals a World Struggling with Poor Sleep

Vaping Expected to Increase COPD Health and Economic Burden by 2050

PAP Therapy Reduces Hospitalizations by 31% and ER Visits by 23% for People with Obstructive Sleep Apnea and Comorbid Insomnia

ResMed's 2024 Global Sleep Survey Uncovers a World in Sleep Crisis

0KW4 - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités